• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

老年人受益于较低的低密度脂蛋白胆固醇。

[Elderly benefit from lower LDL-cholesterol].

作者信息

Wiklund Olov

机构信息

professor emeri-tus, institutionen för medicin, Sahlgrenska akademin, Göteborgs universitet.

出版信息

Lakartidningen. 2021 Mar 24;118:20216.

PMID:33768516
Abstract

In two recent publications LDL-cholesterol and cardiovascular risk in the elderly was studied. A study from Copenhagen shows that LDL-cholesterol is similar as a risk-factor for myocardial infarction in all age-groups. Due to the higher incidence of myocardial infarction with age, the number of events associated with an increased LDL is higher among the elderly. The effect of LDL reduction in the elderly was studied in a meta-analysis including statin studies as well as studies with ezetimibe and PCSK9 inhibitors. The relative risk reduction associated with a reduction of 1 mmol/l of LDL-cholesterol was 26%, similar for patients above or below 75 years of age.  These studies emphasize that reduction of LDL should be considered also in the elderly without many comorbidities.

摘要

在最近的两篇出版物中,对老年人的低密度脂蛋白胆固醇(LDL - 胆固醇)与心血管风险进行了研究。哥本哈根的一项研究表明,LDL - 胆固醇作为心肌梗死的风险因素在所有年龄组中相似。由于心肌梗死的发病率随年龄增长而升高,老年人中与LDL升高相关的事件数量更多。在一项荟萃分析中研究了老年人降低LDL的效果,该荟萃分析包括他汀类药物研究以及依泽替米贝和前蛋白转化酶枯草溶菌素9(PCSK9)抑制剂的研究。LDL - 胆固醇每降低1 mmol/L相关的相对风险降低为26%,75岁以上或以下的患者相似。这些研究强调,对于没有很多合并症的老年人也应考虑降低LDL。

相似文献

1
[Elderly benefit from lower LDL-cholesterol].老年人受益于较低的低密度脂蛋白胆固醇。
Lakartidningen. 2021 Mar 24;118:20216.
2
Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials.他汀类药物和非他汀类 LDL 降低药物在二级预防中的心血管结局影响:随机试验的荟萃分析。
Eur Heart J. 2018 Apr 7;39(14):1172-1180. doi: 10.1093/eurheartj/ehx566.
3
A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular outcomes.基于贝叶斯网络的 PCSK9 抑制剂、他汀类药物和依折麦布联合或不联合他汀类药物用于心血管结局的荟萃分析。
Eur J Prev Cardiol. 2018 May;25(8):844-853. doi: 10.1177/2047487318766612. Epub 2018 Mar 23.
4
Recommendations for use of ezetimibe and/or PCSK9 inhibitors in patients with elevated LDL-C.推荐在 LDL-C 升高的患者中使用依折麦布和/或 PCSK9 抑制剂。
Ann Intern Med. 2022 Aug;175(8):JC86. doi: 10.7326/J22-0060. Epub 2022 Aug 2.
5
Proprotein Convertase Subtilisin-Kexin Type 9 (PCSK9) Inhibitors and Cardiovascular Risk: Does a Further Analysis of the Fourier Trial Suggest Changes in the Target of Lipid Lowering Therapy?前蛋白转化酶枯草溶菌素9型(PCSK9)抑制剂与心血管风险:对傅里叶试验的进一步分析是否提示降脂治疗靶点的变化?
High Blood Press Cardiovasc Prev. 2018 Mar;25(1):5-7. doi: 10.1007/s40292-017-0244-x. Epub 2018 Jan 5.
6
Statins, Ezetimibe, and Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors to Reduce Low-Density Lipoprotein Cholesterol and Cardiovascular Events.他汀类药物、依折麦布和前蛋白转化酶枯草溶菌素9型抑制剂用于降低低密度脂蛋白胆固醇和心血管事件。
Am J Cardiol. 2017 Feb 15;119(4):565-571. doi: 10.1016/j.amjcard.2016.11.001. Epub 2016 Nov 23.
7
Association Between Baseline LDL-C Level and Total and Cardiovascular Mortality After LDL-C Lowering: A Systematic Review and Meta-analysis.降脂治疗后 LDL-C 水平与全因及心血管死亡率的相关性:系统评价和荟萃分析。
JAMA. 2018 Apr 17;319(15):1566-1579. doi: 10.1001/jama.2018.2525.
8
Combination Lipid-Lowering Therapies for the Prevention of Recurrent Cardiovascular Events.降脂联合治疗预防复发性心血管事件。
Curr Cardiol Rep. 2018 May 25;20(7):55. doi: 10.1007/s11886-018-0997-4.
9
Simulation of the Impact of Statin Intolerance on the Need for Ezetimibe and/or Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor for Meeting Low-Density Lipoprotein Cholesterol Goals in a Population With Atherosclerotic Cardiovascular Disease.他汀类药物不耐受对满足动脉粥样硬化性心血管疾病患者低密度脂蛋白胆固醇目标的依折麦布和/或前蛋白转化酶枯草溶菌素 9 抑制剂需求的影响模拟。
Am J Cardiol. 2019 Apr 15;123(8):1202-1207. doi: 10.1016/j.amjcard.2019.01.028. Epub 2019 Jan 25.
10
Comparison of PCSK9 Inhibitor Evolocumab vs Ezetimibe in Statin-Intolerant Patients: Design of the Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin-Intolerant Subjects 3 (GAUSS-3) Trial.在他汀类药物不耐受患者中比较前蛋白转化酶枯草溶菌素9(PCSK9)抑制剂依洛尤单抗与依折麦布:使用抗PCSK9抗体治疗他汀类药物不耐受受试者3(GAUSS-3)试验的目标达成设计
Clin Cardiol. 2016 Mar;39(3):137-44. doi: 10.1002/clc.22518. Epub 2016 Mar 4.